BSE · 531739
Gennex Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹37 Cr with net profit ₹3 Cr — a 8.14% net margin, versus 14.49% the period before.
Shareholding
As of 2026-06-30
- Promoter23.63%
- Public76.37%
- DII0%
82,886 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.45× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #12 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
| Gennex Laboratories Ltd.(this company) | ₹217 Cr | 11.47 | 0.97 | 8.29% | 10.77% |
AI analysis
AI-generated · google/gemini-2.5-flashGennex Laboratories Ltd. is listed with a market capitalization of Rs 228 Cr. The company reported revenue of Rs 148.33 Cr and a profit margin of 10.77%. Its return on equity (ROE) stands at 8.29% and return on capital employed (ROCE) at 9.09%. The book value per share is Rs 9.16, with earnings per share (EPS) at Rs 0.78.
Positives
- +The company maintains a low debt-to-equity ratio of 0.04.
- +The profit margin is 10.77%.
Negatives
- −Promoter shareholding is relatively low at 23.63% as of March 31, 2026.
- −A significant portion of promoter shares, 17.42%, are pledged.
- −Foreign Institutional Investors (FII) holding is 0% as of March 31, 2026.
- −There is no dividend yield reported for the company.
Financial Performance
For the period ending March 2026, the company reported revenue of Rs 36.71 Cr and a net profit of Rs 2.99 Cr. In the preceding quarter, December 2025, revenue was Rs 42.96 Cr with net profit of Rs 5.24 Cr. Quarterly revenue for March 2026 was Rs 60.96 Cr with a net profit of Rs 3.74 Cr.
Profitability & Returns
Gennex Laboratories Ltd. recorded a profit margin of 10.77%. The company's Return on Equity (ROE) is 8.29%, while the Return on Capital Employed (ROCE) is 9.09%. Earnings per share (EPS) for the latest period is Rs 0.78.
Balance Sheet
The company has a debt-to-equity ratio of 0.04, indicating a low level of debt. The book value per share is Rs 9.16. No dividend yield is reported for the company as of the latest data.
Ownership & Pledges
Promoter holding stands at 23.63% as of March 31, 2026, with public shareholding at 76.37%. DII and FII holdings are 0.0015% and 0% respectively. A significant portion of promoter shares, 17.42%, are pledged. Specifically, 10,000,000 shares held by Premier Fiscal Services Private Limited, representing 18.85% of their holding, were pledged as of March 31, 2026.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.